Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA reauthorization, FDA reform will not hold Congress in session -- FDA's Schultz.

This article was originally published in The Tan Sheet

Executive Summary

FDA REFORM/PDUFA REAUTHORIZATION WILL NOT KEEP CONGRESS IN SESSION following passage of the appropriations bills, FDA Deputy Commissioner for Policy William Schultz warned at a Sept. 3 Food & Drug Law Institute meeting in Washington DC. "Important as [the Prescription Drug User Fee Act] is, it is not going to hold Congress in session," Schultz maintained. "There is a very good chance that legislation will pass," Schultz said, "but unfortunately there is also a very real risk that it won't."





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts